News Articles for NeuroScientific Biopharmaceuticals

NeuroScientific Biopharmaceuticals has reached another clinical milestone, with a fourth Crohn's disease patient now receiving its patented StemSmart stem cell therapy for the chronic bowel disease under Australia's Special Access Scheme. The company says data from the real-world program will directly inform the design of its upcoming phase two trial, slated to begin in the second half of 2026.

NeuroScientific Biopharmaceuticals has unveiled positive results from two studies using its stem cell therapy in kidney transplantation. Eight out of 10 patients in a small case series, facing severe organ rejection, retained their donor kidney. A second study showed the treatment was safe and may improve graft function in deceased-donor transplants. The findings have bolstered the company's plans for a wider clinical development in the multibillion-dollar global market.

Perth-based stem cell therapy pioneer NeuroScientific Biopharmaceuticals is transferring its patented StemSmart technology to one of Australia's biggest and most experienced manufacturers to scale up clinical-grade production, ahead of the commercialisation of its infusion therapy for hard-to-treat conditions, starting with Crohn's disease. Queensland-based Q-Gen Cell Therapeutics specialises in manufacturing cellular immunotherapies for national and international clinical trials from 13 cleanrooms dedicated to cell manufacturing and quality control.

Melbourne executive Nathan Smith will take the reins as CEO at NeuroScientific Biopharmaceuticals, bringing his strategic and commercial nous as the company gears up to release its innovative StemSmart stem cell technology. This is the Perth-based biotech's second heavy-hitting appointment, after it recruited a well-credentialled chief medical officer in Perth-based paediatric haematologist and oncologist Dr Catherine Cole.

NeuroScientific Biopharmaceuticals has snagged a well-credentialled WA haematologist and oncologist as its chief medical officer. The company is banking on Dr Catherine Cole's decades of clinical leadership and trials experience to help it roll out its innovative stem cell therapy. A trial is underway to test its stem cell technology to treat patients with a difficult-to-treat complication of Crohn's disease.

NeuroScientific has completed its acquisition of Perth pharmaceuticals company Isopogen WA, which controls the StemSmart technology patent, in a bid to boost its stem cell offerings.

NeuroScientific Biopharmaceuticals has acquired unlisted Perth-based Isopogen for $5.1 million, gaining control of the company's stem cell therapy developed as a last-line treatment for severe autoimmune disease and transplant complications. The move puts NeuroScientific in line to compete in the regenerative space.

This week's Bulls N' Bears ASX Runner of the Week is… Grand Gulf Energy, after it acquired an option over a billion-barrel oil prospect off the coast of Namibia. Meteoric Resources announced a maiden resource for its ionic clay deposit in Brazil, Aus Strategic Materials flourished under US rare earths supply concerns following Chinese export bans and NeuroScientific Biophamaceuticals acquired an innovative and life-changing stem cell technology company.

Shares in the Harold Clough-founded company are on the up as it prepares to buy a new stem cell technology.

NeuroScientific Biopharmaceuticals has appointed Christopher Achurch as company secretary, following the resignation of Abby Macnish Niven as chief financial officer and company se

Our board moves wrap includes Benjamin Donovan, Graeme Morissey, Simon Robertson, John Traicos, Anson Heng, Chris Ntoumenopoulos, Paul Rennie, Tony Keating, and Stephen Quantrill.

Our board moves wrap includes Dianne Angus, Geoff Pocock, Andrew Chapman, Tod McGrouther, Gaurav Gupta, Mark Licciardo, Joel Ives, Karen Logan, Joan Dabon, Harry Spindler, Dan Robinson, Stephen Parker, Ross Walker, Stephen Carter, Grant Lukey, Rhett Morson, Bruce Rathie, Alec PIsmiris, Geoff Stalley, Kenneth Hall, Cathy Moises, and Brady Hall.

Our board moves wrap includes Robert Mosig, Victor Hoo, Gareth Lloyd, Francis De Souza, Clarke Barlow, Chris Ntoumenopoulos, Linda Friedland, Chris Huish, Ben Laurance, Wayne Zekulich, and Robert Milbourne.

Our board moves wrap includes Salome Sijaona, Philip Crutchfield, Ric Dawson, John Hannaford, Linda Friedland, ZaiQian Zhang, Su-Mei Sain, and Benjamin Donovan.

Our board moves wrap includes Andrew Muir, Philip Re, Stephen Carter, Paul Rennie, James Brown, Colin Noid, Joan Dabon, Loren King, Michael Higginson, and Jonathan Lea.

Our board moves wrap includes Ken Kluksdahl, Andre Douchane, Paul Rennie, Mark Elliott, Tim Wall, and Xavier Braud.

Our board moves wrap includes Jessamyn Lyons, Mark Hepburn, Anton Uvarov, Paul Arndt, and Bryant Mclarty.

Our board moves wrap includes Kathleen Bozanic, Rachel Rees, Matthew Liddelow, and Philip Bruce.

The boss of Clough family-backed NeuroScientific Biopharmaceuticals has resigned just days after the national research ethics body refused a trial for its Alzheimer's treatment.

Shares in Clough family-backed NeuroScientific Biopharmaceuticals have plunged after a planned clinical trial for its budding Alzheimer's treatment was rejected by the Human Research Ethics Committee.

Our board moves wrap includes Dan Arazi, Lesa Francis, Reina Nicholls, Paul Rennie, Anton Uvarov, Rebecca Morgan, Kelly O'Rourke, and Nicole Duncan.

Our board moves wrap includes Richard Nicholls-Maltman, Eddy Wu, Mathew Longworth, Andrew Daley, Brian Leedman, Anton Uvarov, and Shaun Hardcastle.

Our weekly appointments wrap includes Sev Isikli, David Buckingham, Katrina Powell, Andrew Bell, Simone Hansen, Dougal Thring, Alexandra Heaton, Clementine Crowther, Sandra Brkic, Doriena Parsons, Susanne Johnston, and Chris Carman.

Nedlands-based NeuroScientific Biopharmaceuticals, which has been bankrolled by the Clough family, is set to begin trading on the ASX tomorrow, after raising $6 million via an initial public offering.